Finally, our study suggests that CPX‐351 may be beneficial also in rare subgroups of s‐AML such as NPM1 mutated and ELN 2017 favorable risk patients or, to a lesser extent, in patients with mutated FLT3‐ITD [36]. This evidence concerns the gene NPM1 and acute myeloid leukemia.